Wall Street analysts predict that Aclaris Therapeutics, Inc. (NASDAQ:ACRS) will post sales of $800,000.00 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Aclaris Therapeutics’ earnings. The highest sales estimate is $1.00 million and the lowest is $600,000.00. The business is scheduled to report its next quarterly earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Aclaris Therapeutics will report full year sales of $800,000.00 for the current financial year, with estimates ranging from $680,000.00 to $1.68 million. For the next fiscal year, analysts forecast that the company will post sales of $23.55 million per share, with estimates ranging from $18.58 million to $28.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.23. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $2.00 million.
Several analysts have weighed in on ACRS shares. Cantor Fitzgerald reissued a “buy” rating and set a $50.00 price objective on shares of Aclaris Therapeutics in a report on Monday, September 18th. Zacks Investment Research raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a report on Tuesday, October 10th. ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. JMP Securities reissued an “outperform” rating and set a $39.00 price objective on shares of Aclaris Therapeutics in a report on Friday, September 8th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $36.00 price objective on shares of Aclaris Therapeutics in a report on Monday, July 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $39.20.
Aclaris Therapeutics (NASDAQ:ACRS) opened at $22.28 on Wednesday. Aclaris Therapeutics has a 52-week low of $20.20 and a 52-week high of $33.25.
Institutional investors and hedge funds have recently modified their holdings of the stock. Citigroup Inc. grew its position in shares of Aclaris Therapeutics by 171.8% in the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 2,726 shares during the period. UBS Group AG boosted its position in Aclaris Therapeutics by 60.4% during the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 1,681 shares during the last quarter. Legal & General Group Plc boosted its position in Aclaris Therapeutics by 98.3% during the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 2,605 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Aclaris Therapeutics during the 3rd quarter worth approximately $142,000. Finally, Bank of Montreal Can boosted its position in Aclaris Therapeutics by 1,793.1% during the 2nd quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 6,760 shares during the last quarter. Institutional investors and hedge funds own 83.22% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.